SMi is delighted to announce its USA Highly Potent Active Pharmaceutical Ingredients conference coming to Boston on the 21th-22th October 2019.
The inaugural HPAPI USA conference will explore how current technologies are streamlining the HPAPI industry with artificial intelligence and machine learning, to improve risk assessment and validation. The latest emerging therapies will be discussed including bispecific antibodies, oncolytic viral complexes and hormones. Will the super-high level 5 banding for these biologics prove effective or inept? Are current containment planning and solutions truly ensuing the health of workers? These questions will be answered along with unique insights including HPAPI manufacturing technologies.
Attend the conference and join our networking platform with industry professionals to provide you with the expertise to overcome challenges.
Oncology Antibody-Drug Conjugates (ADC), the ongoing developments and the containment challenges imposed
How to correctly assess, plan and implement the most cost-effective containment
Emerging HPAPI therapies, oncolytic viruses their potential and challenges
Alternative HPAPI manufacturing technologies to reduce powder exposure and improving safety along with enabling continuous manufacturing
The reality of oncology ADC and HPAPI: are most drugs using ‘highly-potent’ to improve brand image? Has 50 years of ADC R&D for oncology with no cure shows signs of no promise?
View the full agenda: www.hpapi-usa.com/PharmNews
Additional Contact Info:
T: +44 (0) 20 7827 6164
© 2018 PHARMA NEWS HQ, All rights reserved
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.